These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 19877975)
21. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D; BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796 [TBL] [Abstract][Full Text] [Related]
22. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. Flapper BC; Schoemaker MM Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997 [TBL] [Abstract][Full Text] [Related]
23. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440 [TBL] [Abstract][Full Text] [Related]
24. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood? Golubchik P; Kodesh A; Weizman A Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548 [TBL] [Abstract][Full Text] [Related]
26. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903 [No Abstract] [Full Text] [Related]
27. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings. Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511 [No Abstract] [Full Text] [Related]
28. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ; Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578 [TBL] [Abstract][Full Text] [Related]
29. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587 [TBL] [Abstract][Full Text] [Related]
30. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study. Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921 [No Abstract] [Full Text] [Related]
32. [Functioning, comorbidity and treatment of 141 adults with attention deficit hyperactivity disorder (ADHD) at a psychiatric outpatient department]. Kooij JJ; Aeckerlin LP; Buitelaar JK Ned Tijdschr Geneeskd; 2001 Aug; 145(31):1498-501. PubMed ID: 11512422 [TBL] [Abstract][Full Text] [Related]
33. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study. Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237 [TBL] [Abstract][Full Text] [Related]
34. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837 [TBL] [Abstract][Full Text] [Related]
35. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. Jain R; Segal S; Kollins SH; Khayrallah M J Am Acad Child Adolesc Psychiatry; 2011 Feb; 50(2):171-9. PubMed ID: 21241954 [TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Greenhill L; Kollins S; Abikoff H; McCracken J; Riddle M; Swanson J; McGough J; Wigal S; Wigal T; Vitiello B; Skrobala A; Posner K; Ghuman J; Cunningham C; Davies M; Chuang S; Cooper T J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1284-1293. PubMed ID: 17023867 [TBL] [Abstract][Full Text] [Related]
38. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Spencer T; Biederman J; Wilens T; Doyle R; Surman C; Prince J; Mick E; Aleardi M; Herzig K; Faraone S Biol Psychiatry; 2005 Mar; 57(5):456-63. PubMed ID: 15737659 [TBL] [Abstract][Full Text] [Related]
39. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial. Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A; JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084 [TBL] [Abstract][Full Text] [Related]
40. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]